Monitoring programmed death 1 receptor and its ligand on circulating tumor-associated cells in recurrent or metastatic non–small-cell lung cancer predicts response to immunotherapy and radiation.

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.

The clinical application of PD-L1 immunohistochemistry (IHC) testing is complicated by the availability of multiple IHC assays, scoring algorithms, and cutoffs. This study assessed the analytical ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

A first-in-class peptide-based PET tracer, 18F-AlF-NOTA-PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer 18F-FDG. 18F ...

This new study has found different labs followed similar practices, but the way they scored patients varied significantly. Although programmed cell death ligand-1 (PD-L1) is widely recognized as a ...

A clinically meaningful benefit was demonstrated across clinical subgroups, including those with PD-L1 low expression, PD-L1 high expression, squamous and non-squamous histologies.

Key Takeaways Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast ...